Research programme: allergic asthma therapy - GlaxoSmithKline

Drug Profile

Research programme: allergic asthma therapy - GlaxoSmithKline

Alternative Names: Birch pollen extract-protollin; Birch pollen extract/protollin; Protollin adjuvanted birch pollen extract; Protollin-birch pollen extract; Protollin/birch pollen extract

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ID Biomedical Corporation
  • Developer GlaxoSmithKline
  • Class Allergy immunotherapies; Cysteine endopeptidases; Lipoproteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-asthma in Canada (Intranasal, Spray)
  • 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
  • 19 Apr 2005 Preclinical trials in Allergic asthma in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top